MedTrace Logo

The GABAergic Inhibitory System in Drug Resistant Epilepsy

NCT06789497 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2025-01-23

No results posted yet for this study

Summary

This study aims to investigate the effect of lovastatin on neurotransmission and neuroinflammation in patients with temporal lobe onset drug resistant epilepsy.

Structure: (1) Visit 1: 3 consecutive days of physiologically probing drug/placebo intake, (2) Visit 2: Outcome measures and additional evaluations in the day after the last drug/placebo intake, (3) Washout period of 4 weeks, (4) 3 consecutive days of drug/placebo intake, (5) Visit 3: Outcome measures and additional evaluations in the day after the last placebo/drug intake.

Conditions

  • Drug Resistant Epilepsy
  • Temporal Lobe Epilepsy

Interventions

DRUG

Lovastatin 60 MG

Participants were given lovastatin 60 mg/day for three consecutive days.

DRUG

Placebo

Participants were given placebo 60 mg/day for three consecutive days.

Sponsors & Collaborators

  • University of Coimbra

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-12
Primary Completion
2024-01-01
Completion
2024-04-01

Countries

  • Portugal

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06789497 on ClinicalTrials.gov